Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910367513> ?p ?o ?g. }
- W2910367513 endingPage "3380" @default.
- W2910367513 startingPage "3380" @default.
- W2910367513 abstract "Abstract Introduction: Hemorrhagic cystitis (HC) causes significant morbidity following allogeneic hematopoietic cell transplantation (HCT). Reactivation of BK polyoma virus frequently occurs following transplantation and appears to be the most commonly associated factor, although high dose cyclophosphamide, other viruses, and numerous other factors contribute. A higher incidence of BK HC was reported with the use of matched unrelated or cord blood donors compared to HLA-matched siblings (El-Zimaity M, et al. Blood. 2004), however, the intensity of GVHD prevention regimens varied according to cell source complicating interpretation of these data. The effect of HLA-mismatched donors on the incidence of BK HC has been disputed and a large study of mismatched donors detected no association of HC with mismatched compared to matched donors (Giraud G, et al. Bone Marrow Transplant, 2008; Gilis L, et al. Bone Marrow Transplantation, 2014.) We analyzed a cohort of patients biologically assigned to matched sibling (MSD) or haploidentical family donor (based on presence of a suitable MSD donor) who received identical myeloablative or nonablative conditioning regimens and identical PTCy-based GVHD prevention to directly analyze the association of donor source with HC. Methods : To evaluate the role of haploidentical vs MSD donor source, we analyzed all patients undergoing haploidentical or MSD HCT at the Levine Cancer Institute between March 2014 and June 2018. Patients received identical myeloablative (BuCy) or nonmyeloablative (Flu/Cy/TBI) conditioning regimens followed by peripheral blood stem cell grafts and identical PTCy-based regimens which included tacrolimus and mycophenolate for GVHD prevention. The cumulative incidence of HC was calculated in a competing risk setting with death from any cause as a competing event. Group comparisons of incidences were determined by a Gray's test. Cox regression was conducted to evaluate risk factors for the development of HC. It was also used to evaluate HC as a time-dependent risk factor for overall survival. Fisher's exact test was used to analyze categorical patient characteristics, and two-sample t-test was employed for continuous variables. Results : From March 2014 to June 2018, 39 patients (32%) underwent MSD transplantation and 84 patients (68%) received transplants from haploidentical donors. Baseline characteristics were similar except for younger donor age of haploidentical donors (median 40 yrs vs 54 yrs P< .001). The rates of acute GVHD, Chronic GVHD, NRM and overall survival were similar between the two groups. The cumulative incidence of HC was higher in patients who received cells from haploidentical donors when compared to matched related donors (p=0.05). In multivariate analysis of risk factors associated with HC (Table 1), haploidentical donor (HR: 1.80, 95% CI 0.95-3.44, P= .07) and, grade III-IV acute GVHD (HR: 4.93, 95% CI 1.01-23.93 P = .05), were associated with development of HC. 33/53 HC patients (62%) were tested positive for BK virus. The intensity of the conditioning regimen, disease status at transplant, donor and recipient age were not associated with development of HC. For patients who received cells from haploidentical donors, there was a trend towards severe (grade 3-4) HC, but this did not reach statistical significance (HR 2.71, 95% CI 0.59-12.24 P=.19). The incidence of HC was not associated with overall survival (HR 0.58 95% CI 0.3-1.15 P=0.12), even when severe (grade III-IV) HC events were evaluated (HR 1.79 95% CI 0.75-4.3 P=0.19). Conclusions: In adults undergoing allogenic transplantations using identical conditioning regimens and PTCy based GVHD prevention, the use of a haploidentical donor results in a higher incidence of HC than does a MSD. Disclosures Grunwald: Cardinal Health: Consultancy, Membership on an entity's Board of Directors or advisory committees; Forma Therapeutics: Research Funding; Ariad: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Alexion: Consultancy, Membership on an entity's Board of Directors or advisory committees; Medtronic: Equity Ownership; Genentech: Research Funding; Incyte Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Merck: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Research Funding. Jacobs:Genentech: Honoraria. Usmani:Abbvie, Amgen, Celgene, Genmab, Merck, MundiPharma, Janssen, Seattle Genetics: Consultancy; Amgen, BMS, Celgene, Janssen, Merck, Pharmacyclics,Sanofi, Seattle Genetics, Takeda: Research Funding." @default.
- W2910367513 created "2019-01-25" @default.
- W2910367513 creator A5006044740 @default.
- W2910367513 creator A5009378735 @default.
- W2910367513 creator A5019444571 @default.
- W2910367513 creator A5026798441 @default.
- W2910367513 creator A5027193786 @default.
- W2910367513 creator A5035890812 @default.
- W2910367513 creator A5042176968 @default.
- W2910367513 creator A5042992484 @default.
- W2910367513 creator A5043680453 @default.
- W2910367513 creator A5047181107 @default.
- W2910367513 creator A5048056595 @default.
- W2910367513 creator A5052956251 @default.
- W2910367513 creator A5059850025 @default.
- W2910367513 creator A5074766331 @default.
- W2910367513 date "2018-11-29" @default.
- W2910367513 modified "2023-10-01" @default.
- W2910367513 title "Higher Incidence of Hemorrhagic Cystitis after Haploidentical Compared to Matched Sibling Donor Transplantation" @default.
- W2910367513 doi "https://doi.org/10.1182/blood-2018-99-119612" @default.
- W2910367513 hasPublicationYear "2018" @default.
- W2910367513 type Work @default.
- W2910367513 sameAs 2910367513 @default.
- W2910367513 citedByCount "0" @default.
- W2910367513 crossrefType "journal-article" @default.
- W2910367513 hasAuthorship W2910367513A5006044740 @default.
- W2910367513 hasAuthorship W2910367513A5009378735 @default.
- W2910367513 hasAuthorship W2910367513A5019444571 @default.
- W2910367513 hasAuthorship W2910367513A5026798441 @default.
- W2910367513 hasAuthorship W2910367513A5027193786 @default.
- W2910367513 hasAuthorship W2910367513A5035890812 @default.
- W2910367513 hasAuthorship W2910367513A5042176968 @default.
- W2910367513 hasAuthorship W2910367513A5042992484 @default.
- W2910367513 hasAuthorship W2910367513A5043680453 @default.
- W2910367513 hasAuthorship W2910367513A5047181107 @default.
- W2910367513 hasAuthorship W2910367513A5048056595 @default.
- W2910367513 hasAuthorship W2910367513A5052956251 @default.
- W2910367513 hasAuthorship W2910367513A5059850025 @default.
- W2910367513 hasAuthorship W2910367513A5074766331 @default.
- W2910367513 hasBestOaLocation W29103675131 @default.
- W2910367513 hasConcept C120665830 @default.
- W2910367513 hasConcept C121332964 @default.
- W2910367513 hasConcept C126322002 @default.
- W2910367513 hasConcept C143998085 @default.
- W2910367513 hasConcept C203014093 @default.
- W2910367513 hasConcept C2776694085 @default.
- W2910367513 hasConcept C2776755627 @default.
- W2910367513 hasConcept C2777408962 @default.
- W2910367513 hasConcept C2777600175 @default.
- W2910367513 hasConcept C2778199330 @default.
- W2910367513 hasConcept C2779972918 @default.
- W2910367513 hasConcept C2780007613 @default.
- W2910367513 hasConcept C2780303639 @default.
- W2910367513 hasConcept C2909675724 @default.
- W2910367513 hasConcept C2911091166 @default.
- W2910367513 hasConcept C61511704 @default.
- W2910367513 hasConcept C71924100 @default.
- W2910367513 hasConcept C72563966 @default.
- W2910367513 hasConcept C88879693 @default.
- W2910367513 hasConcept C90924648 @default.
- W2910367513 hasConceptScore W2910367513C120665830 @default.
- W2910367513 hasConceptScore W2910367513C121332964 @default.
- W2910367513 hasConceptScore W2910367513C126322002 @default.
- W2910367513 hasConceptScore W2910367513C143998085 @default.
- W2910367513 hasConceptScore W2910367513C203014093 @default.
- W2910367513 hasConceptScore W2910367513C2776694085 @default.
- W2910367513 hasConceptScore W2910367513C2776755627 @default.
- W2910367513 hasConceptScore W2910367513C2777408962 @default.
- W2910367513 hasConceptScore W2910367513C2777600175 @default.
- W2910367513 hasConceptScore W2910367513C2778199330 @default.
- W2910367513 hasConceptScore W2910367513C2779972918 @default.
- W2910367513 hasConceptScore W2910367513C2780007613 @default.
- W2910367513 hasConceptScore W2910367513C2780303639 @default.
- W2910367513 hasConceptScore W2910367513C2909675724 @default.
- W2910367513 hasConceptScore W2910367513C2911091166 @default.
- W2910367513 hasConceptScore W2910367513C61511704 @default.
- W2910367513 hasConceptScore W2910367513C71924100 @default.
- W2910367513 hasConceptScore W2910367513C72563966 @default.
- W2910367513 hasConceptScore W2910367513C88879693 @default.
- W2910367513 hasConceptScore W2910367513C90924648 @default.
- W2910367513 hasIssue "Supplement 1" @default.
- W2910367513 hasLocation W29103675131 @default.
- W2910367513 hasOpenAccess W2910367513 @default.
- W2910367513 hasPrimaryLocation W29103675131 @default.
- W2910367513 hasRelatedWork W2060250861 @default.
- W2910367513 hasRelatedWork W2136804539 @default.
- W2910367513 hasRelatedWork W2142493118 @default.
- W2910367513 hasRelatedWork W2336316221 @default.
- W2910367513 hasRelatedWork W2601152726 @default.
- W2910367513 hasRelatedWork W2910367513 @default.
- W2910367513 hasRelatedWork W2911644904 @default.
- W2910367513 hasRelatedWork W3028603927 @default.
- W2910367513 hasRelatedWork W3119306815 @default.
- W2910367513 hasRelatedWork W3139062822 @default.
- W2910367513 hasVolume "132" @default.
- W2910367513 isParatext "false" @default.
- W2910367513 isRetracted "false" @default.
- W2910367513 magId "2910367513" @default.